跳至主要内容
临床试验/NCT00332904
NCT00332904Unknown4 期

Effect of Betablocker or Aldosterone Antagonist Therapy on Oxygenation, Peripheral and Cardiac Hemodynamics and Humoral Systems

Hvidovre University Hospital1 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2006年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
22
试验地点
1
主要终点
effect of treatment on hemodynamic and cardiac parameters

研究概览

简要总结

The study´s purpose is to investigate the effect of beta blockade or aldosterone antagonist therapy on oxygenation, peripheral and cardiac hemodynamics and humoral systems, in patients with liver cirrhosis.

详细描述

Cardio-pulmonal complications to patients with liver cirrhosis and portal hypertension determine the patients' prognosis. Most patients have hemodynamical changes in circulation with increased cardiac output and decreased systolic function in stress. Endothelial dysfunction is a parameter for bad prognosis in cardiovascular disease. The Renin-angiotensin-aldosterone-system plays an important role in natrium and volume regulation. Descriptions of changes in the peripheral circulation and oxygenation have been deficient up to now.

Patients with liver cirrhosis and portal hypertension are betablockers and/or aldosterone antagonists routine treatment - effects on peripheral hemodynamics and oxygenation in relation to central hemodynamic changes are deficient.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Liver cirrhosis
  • Clinical indication for treatment with betablocker or aldosterone antagonist
  • Must not have been treated earlier with betablocker or aldosterone antagonist
  • Must have been alcohol abstinent for more than 4 weeks

排除标准

  • Gastrointestinal bleeding in the last 2 weeks
  • Encephalopathy > grade 1
  • Acute medical conditions
  • Malignant disease
  • Pregnancy

研究组 & 干预措施

beta

Active Comparator

patients with liver cirrhosis, treated with betablocker

干预措施: propranolol (Drug)

spiron

Active Comparator

patients with liver cirrhosis, treated with aldosterone antagonist

干预措施: spironolactone (Drug)

结局指标

主要结局

effect of treatment on hemodynamic and cardiac parameters

时间窗: 3 weeks

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验